Anti-idiotype immunization of cancer patients: modulation of the immune response.
AUTOR(ES)
Herlyn, D
RESUMO
Thirty patients with advanced colorectal carcinoma (CRC) were treated with alum-precipitated polyclonal goat anti-idiotypic antibodies (Ab2) to monoclonal anti-CRC antibody CO17-1A (Ab1) in doses between 0.5 and 4 mg per injection. All patients developed anti-anti-idiotypic antibodies (Ab3) with binding specificities on the surfaces of cultured tumor cells similar to the specificity of Ab1. Furthermore, the Ab3 competed with Ab1 for binding to CRC cells. Fractions of Ab3-containing sera obtained after elution of the serum immunoglobulins from CRC cells bound to purified tumor antigen and inhibited binding of Ab2 to Ab1. The Ab3, therefore, may share idiotopes with Ab1. Six patients showed partial clinical remission and seven patients showed arrest of metastases following immunotherapy. Four of the thirteen patients with measurable clinical responses had received Ab2 alone, whereas 9 patients had also received chemotherapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=299476Documentos Relacionados
- Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?
- Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine.
- Blocking of pregnancy in mice by immunization with anti-idiotype directed against monoclonal anti-progesterone antibody.
- Protective anti-idiotype antibodies in the primate model of pyelonephritis.
- Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma
